A Phase Ib open label study to assess the safety and pharmacokinetics of
NUC-3373, a nucleotide analogue, given in combination with standard
agents used in colorectal cancer treatment
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Other exclusion criteria may apply.